"Fees, Pharmaceutical" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Amounts charged to the patient or third-party payer for medication. It includes the pharmacist's professional fee and cost of ingredients, containers, etc.
| Descriptor ID |
D005252
|
| MeSH Number(s) |
N03.219.442.551
|
| Concept/Terms |
Fees, Pharmaceutical- Fees, Pharmaceutical
- Fees, Pharmaceutic
- Fee, Pharmaceutic
- Pharmaceutic Fee
- Pharmaceutic Fees
- Pharmacy Fee
- Pharmaceutical Fees
- Fee, Pharmaceutical
- Pharmaceutical Fee
- Fee, Pharmacy
- Fees, Pharmacy
- Pharmacy Fees
|
Below are MeSH descriptors whose meaning is more general than "Fees, Pharmaceutical".
Below are MeSH descriptors whose meaning is more specific than "Fees, Pharmaceutical".
This graph shows the total number of publications written about "Fees, Pharmaceutical" by people in this website by year, and whether "Fees, Pharmaceutical" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fees, Pharmaceutical" by people in Profiles.
-
Luiza VL, Chaves LA, Silva RM, Emmerick IC, Chaves GC, Fonseca de Ara?jo SC, Moraes EL, Oxman AD. Pharmaceutical policies: effects of cap and co-payment on rational use of medicines. Cochrane Database Syst Rev. 2015 May 08; (5):CD007017.
-
Briesacher BA, Zhao Y, Madden JM, Zhang F, Adams AS, Tjia J, Ross-Degnan D, Gurwitz JH, Soumerai SB. Medicare part D and changes in prescription drug use and cost burden: national estimates for the Medicare population, 2000 to 2007. Med Care. 2011 Sep; 49(9):834-41.
-
Miranda ES, Pinto Cdu B, dos Reis AL, Emmerick IC, Campos MR, Luiza VL, Osorio-de-Castro CG. [Availability of generic drugs in the public sector and prices in the private sector in different regions of Brazil]. Cad Saude Publica. 2009 Oct; 25(10):2147-58.
-
Chernew M, Gibson TB, Yu-Isenberg K, Sokol MC, Rosen AB, Fendrick AM. Effects of increased patient cost sharing on socioeconomic disparities in health care. J Gen Intern Med. 2008 Aug; 23(8):1131-6.
-
Shea DG, Terza JV, Stuart BC, Briesacher B. Estimating the effects of prescription drug coverage for Medicare beneficiaries. Health Serv Res. 2007 Jun; 42(3 Pt 1):933-49.
-
Gaskin DJ, Briesacher BA, Limcangco R, Brigantti BL. Exploring racial and ethnic disparities in prescription drug spending and use among Medicare beneficiaries. Am J Geriatr Pharmacother. 2006 Jun; 4(2):96-111.
-
Briesacher BA, Stuart B, Ren X, Doshi JA, Wrobel MV. Medicare beneficiaries and the impact of gaining prescription drug coverage on inpatient and physician spending. Health Serv Res. 2005 Oct; 40(5 Pt 1):1279-96.
-
Andrade SE, Gurwitz JH. Drug benefit plans under managed care: to what extent do older subscribers selecting less drug coverage put themselves at increased financial risk? J Am Geriatr Soc. 2002 Jan; 50(1):178-81.
-
Soumerai SB, Ross-Degnan D, Avorn J, McLaughlin Tj, Choodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med. 1991 Oct 10; 325(15):1072-7.